Nephrol Dial Transplant (2004) 19: 723-726
Nephrol Dial Transplant Vol. 19 No. 3 (c) ERA-EDTA 2004; all rights reserved
Case Report
Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient
1Division of Nephrology, 2Department of Pathology and 3Division of Haematology, The Chaim Sheba Medical Centre, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Correspondence and offprint requests to: M. Kunin, MD, Division of Nephrology and Hypertension, Chaim Sheba Medical Centre, Tel-Hashomer 52621, Israel. Email: m_bilu_k@netvision.net.il
Keywords: apoptosis; bisphosphonates; collapsing glomerulopathy; multiple myeloma; pamidronate
| The first 10% of the full text of this article appears below. |
 |
Introduction |
|---|
Bisphosphonates currently are important antiresorptive agents used in the treatment of metabolic bone diseases, including tumour-associated osteolysis and hypercalcaemia, Paget's disease and osteoporosis. These drugs cause a loss of the osteoclast ruffled border, disruption of the osteoclast cytoskeleton and inhibition of actin ring formation, sufficient to prevent bone resorption [1]. Several studies have demonstrated that high concentrations of bisphosphonates can cause apoptotic cell death of mouse, rat and rabbit osteoclasts in vitro and in vivo by inhibiting the mevalonate pathway and protein prenylation [2]. Bisphosphonates are excreted unchanged via the kidneys. The high drug levels attained in the kidney may cause renal toxicity through a mechanism similar to that described in osteoclasts.
Short-term [3] and long-term [4–6] tubular toxicity of pamidronate were reported in humans. Recently, an association between collapsing glomerulopathy
|
Case |
|---|
|
Discussion |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Bodmer, P. Amico, M. J. Mihatsch, M. Haschke, O. Kummer, S. Krahenbuhl, and M. Mayr Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2366 - 2370. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bergner, D. M. Henrich, M. Hoffmann, A. Honecker, G. Mikus, B. Nauth, D. Nagel, and M. Uppenkamp Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function J. Clin. Pharmacol., August 1, 2007; 47(8): 942 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Kyle, G. C. Yee, M. R. Somerfield, P. J. Flynn, S. Halabi, S. Jagannath, R. Z. Orlowski, D. G. Roodman, P. Twilde, and K. Anderson American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma J. Clin. Oncol., June 10, 2007; 25(17): 2464 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Albaqumi, T. J. Soos, L. Barisoni, and P. J. Nelson Collapsing Glomerulopathy J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2854 - 2863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanvetyanon and P. J. Stiff Management of the adverse effects associated with intravenous bisphosphonates Ann. Onc., June 1, 2006; 17(6): 897 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Body, T. Pfister, and F. Bauss Preclinical Perspectives on Bisphosphonate Renal Safety Oncologist, October 1, 2005; 10(suppl_1): 3 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanvetyanon Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer J Natl Cancer Inst, January 5, 2005; 97(1): 70 - 70. [Full Text] [PDF]
|
|
|
|
|
|
B. D. Humphreys, R. J. Soiffer, and C. C. Magee Renal Failure Associated with Cancer and Its Treatment: An Update J. Am. Soc. Nephrol., January 1, 2005; 16(1): 151 - 161. [Full Text] [PDF]
|
|